$MCK

Rodgers Thomas L sold $514K of MCK

Rodgers Thomas L (EVP, Chief Strategy & BDO) sold 699 shares of MCKESSON CORP (MCK) at $735.27 ($0.51M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rodgers Thomas L
Published Jun 3, 2026, 3:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 3:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MCK
Neutral
medium confidence
Mentioned
$MCK
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

This disclosure updates the insider-trading tape for MCK but does not introduce new company fundamentals in the article.

02

Market read

A routine insider sale with 10b5-1 reduces fundamental read-through; any price effect is likely limited and short-lived.

03

What to watch

Traders may overreact to single Form 4 prints; the more relevant signal would be a pattern of consecutive sales or changes in plan size/pace.

Relevance 6/10Novelty 6/10Timing: Filed today (2026-06-03) disclosing a sale executed 2026-06-02

Background

SEC Form 4 reports insider transactions; a 10b5-1 plan means trades were scheduled in advance and are often less informative about near-term views.

Company-level read

Ticker impact

$MCKNeutralMedium confidence
Context

McKesson EVP Chief Strategy sold 699 shares (~$514K) in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and should fade unless follow-on selling accelerates.

Evidence & confidence

The filing is a routine insider transaction with stated 10b5-1 plan, reducing the signal of new negative information.

Market effects

Minimal; this is company-specific insider activity with no stated operational or regulatory trigger.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect diversification/tax planning rather than bearish expectations.

Key entities

  • McKesson

    Subject of the Form 4 insider sale by an EVP under a pre-arranged 10b5-1 plan.

  • Rodgers Thomas L

    EVP, Chief Strategy & BDO who sold 699 shares at $735.27 on 2026-06-02.

Related articles

$MCKMed

McKesson Q1 Earnings Call Highlights

McKesson (NYSE: MCK) reported Q1 results supported by higher prescription and specialty volumes, partially offset by lower branded-drug pricing. GLP-1 distribution revenue rose to $15B, up about $3B (24%). Full-year guidance calls for North American Pharmaceutical revenue growth of 4% to 8%. Oncology & Multispecialty profit rose 41% to $405M. McKesson repurchased $2.5B shares and expects FY27 FCF $4.5B to $4.9B.

$MCKMedAI 8/10

Highlights of McKesson’s (MCK) Q1 2027 earnings report

McKesson (MCK) reported Q1 fiscal 2027 results. Adjusted earnings rose to $9.93 per share from $8.26 a year earlier, beating analysts. Unadjusted net income was $614 million, or $5.17 per share. Revenue increased to $105.4 billion from $97.83 billion. The company raised FY27 adjusted EPS guidance to $44.20 to $45.00.

$MCKHighAI 9/10

[MCK Q1 2027 Earnings Call] McKesson Lifts Full-Year EPS Target as North American Pharma Profit Soars 19% — BigGo Finance

McKesson reported fiscal Q1 2027 revenue of $105.4B, up 8%, and adjusted EPS of $9.93, up 20%, citing stronger North American Pharmaceutical margins. North American Pharma operating profit rose 19% to $894M on 5% revenue growth, with GLP-1 distribution revenue at $15B (+24%). McKesson raised full-year adjusted EPS guidance to $44.20–$45.00 and returned $2.6B to shareholders.